Table 1. Co-medication of drugs whose metabolism or P-glycoprotein-mediated transport can be induced by SJW, in patients with detectable hyperforin and/or hypericin in their plasma.
| Hyperforin plasma concentration [ng ml−1] (day of hospitalization) | Hypericin plasma concentration [ng ml−1] (day of hospitalization) | ||||||
|---|---|---|---|---|---|---|---|
| Patient | Drugs | Sample 1 | Sample 2 | Sample 3 | Sample 1 | Sample 2 | Sample 3 |
| 3 | Amlodipine (C), atorvastatin (C) | 30.2 (1) | 21.0 (3) | – | 1.3 (1) | 1.8 (3) | – |
| 6 | Diltiazem (C), theophylline (A: case report + B1) | 2.6 (1) | 1.5 (4) | – | <LOQ (1) | <LOQ (4) | – |
| 7 | Atorvastatin (C) | 2.0 (1) | 1.1 (4) | 0.5 (9) | <LOQ (1) | <LOQ (4) | <LOQ (9) |
| 8 | Atorvastatin (C), conjugated oestrogens (A), Diazepam (B1 + B2) | 1.0 (1) | 0.6 (5) | – | <LOQ (1) | <LOQ (5) | – |
| 9 | Atorvastatin (C), diazepam (B1 + B2) | 0.3 (1) | 0.3 (3) | – | <LOQ (1) | <LOQ (3) | – |
| 10 | Simvastatin (A), amlodipine (C) | 0.2 (1) | 0.1 (3) | – | <LOQ (1) | <LOQ (3) | – |
| 11 | Diazepam (B1 + B2) | 0.1 (1) | 0.1 (3) | – | <LOQ (1) | <LOQ (3) | – |
< LOQ = below limit of quantification (0.05 ng ml−1); –= discharge of the patient from model ward before third sampling time; A = interaction established between this drug and SJW; B1 = interaction established between this drug and rifampicin; B2 = interaction established between other representatives of this chemical and SJW; C = substrate of CYP enzymes or P-glycoprotein that are induced by SJW.